| Outcome Measures: |
Primary: Serum concentration of palmitoylcarnitine following 30 days of fenofibrate treatment, Percentage change in serum concentration of palmitoylcarnitine following 30 days of fenofibrate treatment compared to baseline, Baseline and after 30 days of treatment|Serum concentration of acetylcarnitine following 30 days of fenofibrate treatment, Percentage change in serum concentration of acetylcarnitine following 30 days of fenofibrate treatment compared to baseline, Baseline and after 30 days of treatment|Serum concentration of leucine following 30 days of fenofibrate treatment, Percentage change in serum concentration of leucine following 30 days of fenofibrate treatment compared with baseline, Baseline and after 30 days of treatment|Serum concentration of isoleucine following 30 days of fenofibrate treatment, Percentage change in serum concentration of isoleucine following 30 days of fenofibrate treatment compared with baseline, Baseline and after 30 days of treatment|Serum concentration of valine following 30 days of fenofibrate treatment, Percentage change in serum concentration of valine following 30 days of fenofibrate treatment compared with baseline, Baseline and after 30 days of treatment|Triglyceride concentration following 30 days of fenofibrate treatment, Absolute change in serum triglyceride (mmol/L) concentration following 30 days of fenofibrate treatment with baseline, Baseline and after 30 days of treatment | Secondary: Change in ETDRS scale following 30 days of fenofibrate treatment, Change in ETDRS scale following 30 days of fenofibrate treatment, Baseline and after 30 days of treatment
|
